BioRestorative Therapies, Inc.

Good afternoon, everyone, and welcome to the BioRestorative Therapies First Quarter 2025 Investor Call. At this time, all participants are in a listen-only mode, and the floor will be open for questions following the presentation. If anyone should require operator assistance during the conference, please press star zero on your phone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Stephen Kilmer, Investor Relations. Stephen, the floor is yours.

Thank you, Jenny. Good afternoon, everyone. Let me start by pointing out that this conference call will include four looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All four looking statements are based on biorestorative therapy's current beliefs, assumptions, and expectations. And such statements involve known and unknown risks, uncertainties, and other factors that that may cause actual results, performance, or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed. For details on factors, among others, that could affect expectations, see Part 1, Item 1A of our annual report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. BioRestorative undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law. On the call today representing the company are Lance Allspot, BioRestorative's chairman and chief executive officer, Francisco Silva, its vice president of research and development, and Robert Kristol, the company's chief financial officer. With that said, I'll now turn the call over to Les.

Thank you, Stephen. Good afternoon, everyone. Welcome to our first quarter conference call. On behalf of BioRestorative, I'd like to thank you for your interest in our company. And for those of you who are shareholders, as always, we appreciate your support. As you can see from the press release we issued just a short time ago, We have continued to execute well across all areas of our business since the start of 2025. And we have a lot of exciting things to look forward to as we move throughout the year. With that said, I'm going to ask Rob to provide a brief overview of our first quarter financial results.